000020.KO Dongwha Pharm.Co.Ltd
- Market cap
- KRW 144B
- P/E
- 8.0x
- P/B
- 0.37x
- ROE
- 8.4%
- Dividend yield
- 3.47%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 000020.KO undervalued?
Graham number000020.KO trades 64.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dongwha Pharm.Co.Ltd fundamental analysis
No fundamental analysis for Dongwha Pharm.Co.Ltd yet.
Dongwha Pharm.Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dongwha Pharm.Co.Ltd
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic ana…
Full company profileDongwha Pharm.Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dongwha Pharm.Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 237B | 259B | 307B | 307B | 272B | 293B | 340B | 361B | 465B | 496B | 535B |
| Gross Profit | 103B | 108B | 116B | 122B | 139B | 149B | 181B | 190B | 214B | 219B | 238B |
| Operating Income | 11.3B | 11.0B | 11.2B | 9.92B | 23.2B | 22.5B | 29.9B | 18.8B | 13.4B | 257M | 43.0B |
| EBITDA | - | 22.5B | 22.6B | 28.3B | 44.6B | 39.0B | 36.0B | 51.2B | 28.7B | 32.5B | 59.9B |
| Net Income | 26.3B | 47.0B | 10.1B | 9.40B | 28.5B | 17.9B | 20.4B | 27.4B | 5.56B | 8.69B | 33.3B |
| EPS | - | 1,703 | 365 | 341 | 1,033 | 646 | 736 | 991 | 201 | 313 | 1,202 |
| Balance Sheet | |||||||||||
| Total Assets | 325B | 367B | 371B | 376B | 434B | 448B | 461B | 565B | 620B | 642B | 654B |
| Total Liabilities | 71.7B | 70.3B | 73.2B | 75.2B | 91.1B | 87.7B | 82.5B | 158B | 218B | 241B | 238B |
| Shareholders' Equity | 253B | 297B | 297B | 301B | 331B | 347B | 364B | 372B | 373B | 380B | 395B |
| Cash & Short-term Investments | 35.7B | 31.6B | 40.6B | 37.8B | 58.6B | 60.5B | 34.3B | 72.3B | 25.7B | 13.3B | 22.1B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 25.5B | -16.5B | -4.36B | 13.3B | 52.2B | 36.0B | 29.2B | 29.2B | -4.00B | 15.7B | 38.1B |
| Capital Expenditure | 2.50B | 3.03B | 3.46B | 4.80B | 34.2B | 21.9B | 18.4B | 26.3B | 74.1B | 55.3B | 13.3B |
| Free Cash Flow | - | -19.9B | -8.06B | 7.78B | 22.1B | 11.3B | 9.13B | 2.82B | -78.1B | -39.6B | 24.7B |
| Ratios | |||||||||||
| ROE | 10.4% | 15.8% | 3.4% | 3.1% | 8.6% | 5.2% | 5.6% | 7.4% | 1.5% | 2.3% | 8.4% |
| ROA | 8.1% | 12.8% | 2.7% | 2.5% | 6.6% | 4.0% | 4.4% | 4.9% | 0.9% | 1.4% | 5.1% |
| Net Profit Margin | 11.1% | 18.2% | 3.3% | 3.1% | 10.5% | 6.1% | 6.0% | 7.6% | 1.2% | 1.7% | 6.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dongwha Pharm.Co.Ltd dividends
- Dividend yield
- 3.47%
- Forward dividend
- 65.00 KRW
- Payout ratio
- 57.4%
- Ex-dividend date
- Mar 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 4.99B | 180 | 57.4% |
| 2024 | KRW 4.99B | 180 | 89.7% |
| 2023 | KRW 4.98B | 180 | 18.2% |
| 2022 | KRW 4.98B | 180 | 24.4% |
| 2021 | KRW 4.97B | 180 | 27.8% |
| 2020 | KRW 3.31B | 120 | 11.6% |
| 2019 | KRW 3.31B | 120 | 35.2% |
| 2018 | KRW 4.14B | 150 | 41.1% |
| 2017 | KRW 3.04B | 110 | 6.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Jul 2, 2009.
Who owns Dongwha Pharm.Co.Ltd
- Insiders 38.25%
- Institutions 1.22%
- Public & others 60.53%
- Shares outstanding 27.7M
- Free float 18.8M
Dongwha Pharm.Co.Ltd company profile
- Company name
- Dongwha Pharm.Co.Ltd
- Ticker
- 000020.KO
- ISIN
- KR7000020008
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 795
- Fiscal year end
- December
- Address
- FastFive Tower, Seoul, South Korea, 04522
- Phone
- 82 2 2021 9300
- Website
- dong-wha.co.kr
About Dongwha Pharm.Co.Ltd
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company also exports its products. Dongwha Pharm.Co.,Ltd was founded in 1897 and is headquartered in Seoul, South Korea.
Dongwha Pharm.Co.Ltd management
2- Prof. Doh Joon Yoon M.D., Ph.D.Chairman of the Board & Co-CEO · born 1952
- Mr. Chang-Soo ChoCo-CEO & President · born 1949